361 related articles for article (PubMed ID: 32892365)
1. Circulating lipidomic alterations in obese and non-obese subjects with non-alcoholic fatty liver disease.
Jung Y; Lee MK; Puri P; Koo BK; Joo SK; Jang SY; Lee DH; Jung YJ; Kim BG; Lee KL; Park TS; Kang KT; Ryu DH; Kang SW; Kim D; Oh S; Kim W; Hwang GS
Aliment Pharmacol Ther; 2020 Nov; 52(10):1603-1614. PubMed ID: 32892365
[TBL] [Abstract][Full Text] [Related]
2. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
Ooi GJ; Meikle PJ; Huynh K; Earnest A; Roberts SK; Kemp W; Parker BL; Brown W; Burton P; Watt MJ
J Hepatol; 2021 Sep; 75(3):524-535. PubMed ID: 33887358
[TBL] [Abstract][Full Text] [Related]
3. Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes.
Bayliss J; Ooi GJ; De Nardo W; Shah YJH; Montgomery MK; McLean C; Kemp W; Roberts SK; Brown WA; Burton PR; Watt MJ
Front Endocrinol (Lausanne); 2021; 12():642432. PubMed ID: 33746906
[TBL] [Abstract][Full Text] [Related]
4. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
[TBL] [Abstract][Full Text] [Related]
5. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
6. A Pilot Study of Serum Sphingomyelin Dynamics in Subjects with Severe Obesity and Non-alcoholic Steatohepatitis after Sleeve Gastrectomy.
Ramos-Molina B; Castellano-Castillo D; Pastor O; Ocaña-Wilhelmi L; Fernández-García D; Romero-Gómez M; Cardona F; Tinahones FJ
Obes Surg; 2019 Mar; 29(3):983-989. PubMed ID: 30488259
[TBL] [Abstract][Full Text] [Related]
7. Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity.
Barchetta I; Enhörning S; Cimini FA; Capoccia D; Chiappetta C; Di Cristofano C; Silecchia G; Leonetti F; Melander O; Cavallo MG
BMC Med; 2019 Apr; 17(1):85. PubMed ID: 31035998
[TBL] [Abstract][Full Text] [Related]
8. Irisin in patients with nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
[TBL] [Abstract][Full Text] [Related]
9. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
[TBL] [Abstract][Full Text] [Related]
10. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study.
Perakakis N; Polyzos SA; Yazdani A; Sala-Vila A; Kountouras J; Anastasilakis AD; Mantzoros CS
Metabolism; 2019 Dec; 101():154005. PubMed ID: 31711876
[TBL] [Abstract][Full Text] [Related]
11. Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease.
Lefere S; Van de Velde F; Devisscher L; Bekaert M; Raevens S; Verhelst X; Van Nieuwenhove Y; Praet M; Hoorens A; Van Steenkiste C; Van Vlierberghe H; Lapauw B; Geerts A
Int J Obes (Lond); 2017 Aug; 41(8):1207-1213. PubMed ID: 28461687
[TBL] [Abstract][Full Text] [Related]
12. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
[TBL] [Abstract][Full Text] [Related]
13. Serum Monounsaturated Triacylglycerol Predicts Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease and Chronic Hepatitis B.
Yang RX; Hu CX; Sun WL; Pan Q; Shen F; Yang Z; Su Q; Xu GW; Fan JG
Sci Rep; 2017 Sep; 7(1):10517. PubMed ID: 28874844
[TBL] [Abstract][Full Text] [Related]
14. Association between circulating bile acid alterations and nonalcoholic steatohepatitis independent of obesity and diabetes mellitus.
Jung Y; Koo BK; Jang SY; Kim D; Lee H; Lee DH; Joo SK; Jung YJ; Park JH; Yoo T; Choi M; Lee MK; Kang SW; Chang MS; Kim W; Hwang GS;
Liver Int; 2021 Dec; 41(12):2892-2902. PubMed ID: 34358397
[TBL] [Abstract][Full Text] [Related]
15. Lipidomic identification of urinary extracellular vesicles for non-alcoholic steatohepatitis diagnosis.
Zhu Q; Li H; Ao Z; Xu H; Luo J; Kaurich C; Yang R; Zhu PW; Chen SD; Wang XD; Tang LJ; Li G; Huang OY; Zheng MH; Li HP; Liu F
J Nanobiotechnology; 2022 Jul; 20(1):349. PubMed ID: 35897102
[TBL] [Abstract][Full Text] [Related]
16. Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD.
Polyzos SA; Perakakis N; Boutari C; Kountouras J; Ghaly W; Anastasilakis AD; Karagiannis A; Mantzoros CS
J Clin Endocrinol Metab; 2020 Mar; 105(3):e390-400. PubMed ID: 31690932
[TBL] [Abstract][Full Text] [Related]
17. Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease.
Pacifico L; Di Martino M; De Merulis A; Bezzi M; Osborn JF; Catalano C; Chiesa C
Hepatology; 2014 Feb; 59(2):461-70. PubMed ID: 23843206
[TBL] [Abstract][Full Text] [Related]
18. Increased Plasma Proneurotensin Levels Identify NAFLD in Adults With and Without Type 2 Diabetes.
Barchetta I; Cimini FA; Leonetti F; Capoccia D; Di Cristofano C; Silecchia G; Orho-Melander M; Melander O; Cavallo MG
J Clin Endocrinol Metab; 2018 Jun; 103(6):2253-2260. PubMed ID: 29590379
[TBL] [Abstract][Full Text] [Related]
19. Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity.
Di Mauro S; Scamporrino A; Petta S; Urbano F; Filippello A; Ragusa M; Di Martino MT; Scionti F; Grimaudo S; Pipitone RM; Privitera G; Di Pino A; Scicali R; Valenti L; Dongiovanni P; Fracanzani A; Rabuazzo AM; Craxì A; Purrello M; Purrello F; Piro S
Liver Int; 2019 Sep; 39(9):1742-1754. PubMed ID: 31169972
[TBL] [Abstract][Full Text] [Related]
20. Circulating Phospholipid Patterns in NAFLD Patients Associated with a Combination of Metabolic Risk Factors.
Tiwari-Heckler S; Gan-Schreier H; Stremmel W; Chamulitrat W; Pathil A
Nutrients; 2018 May; 10(5):. PubMed ID: 29883377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
